Price
No data yet.
Social Signal Score
Analyst Ratings
11 analystsRevenue
$77.19M+51.80%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Kevin R. Smith
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 753
- Beta
- 1.50
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 1.23
Financials
Revenue
$77.19M+51.8%Net Income
$-16.16M-407.1%EBITDA
$-14.64M-255.1%Free Cash Flow
$-7.17M-314.1%EPS (diluted)
$-0.61-344.0%Shares Outstanding (diluted)
26.46M+23.9%Operating Expenses
$39.03MCash & Debt
$96.84MReturn of Capital
$3.75MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $348.67M | $-22.75M | $-0.85 |
| 2024 | $335.70M | $-35.89M | $-1.52 |
| 2023 | $315.66M | $-102.45M | $-4.42 |
| 2022 | $377.24M | $-83.77M | $-3.67 |
| 2021 | $358.00M | $-6.33M | $-0.28 |
| 2020 | $308.49M | $-5.83M | $-0.27 |
| 2019 | $361.94M | $20.95M | $0.96 |
| 2018 | $358.11M | $51.84M | $2.30 |
| 2017 | $249.44M | $21.00M | $1.02 |
| 2016 | $202.83M | $20.52M | $1.02 |
| 2015 | $159.00M | $11.59M | $0.60 |
| 2014 | $112.54M | $6.83M | $0.33 |
| 2013 | $75.44M | $25.43M | $1.01 |
| 2012 | $48.58M | $564.0K | $-0.36 |
Valuation
INGNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100-21.05%Social Signal Score
Mentions (7)
- Newsseekingalpha.com·16d ago·Neutral
Inogen, Inc. (INGN) Q3 2026 Earnings Call Transcript Inogen, Inc. ( INGN ) Q3 2026 Earnings Call November 5, 2026 5:00 PM EST Company Participants Lorna Williams - Senior Vice President of Investor Relations Andrew Reding - President, CEO & Director Jason Richardson - CFO, Executive VP & Treasurer Presentation Operator Welcome to Inogen's Third Quarter 2026 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded today, November -- as a reminder, this co…
View source ↗ - Newsmarketbeat.com·17d ago·Negative
What Inogen (INGN) Said on Its Q3 Earnings Call Inogen NASDAQ: INGN reported lower third-quarter revenue as weaker spending by large European customers offset a return to growth in U.S. sales. The respiratory care company also outlined a $20 million annualized cost-reduction program following the sale of its U.S. oxygen rental business.
View source ↗ - Newsseekingalpha.com·33d ago·Positive
Inogen: Cheap Enough To Take A Chance On Inogen, Inc. (INGN) is upgraded to Buy, driven by operational improvement with support from a robust balance sheet. INGN's $45m share buyback, debt-free status, and cash/investments covering ~61% of market cap provide downside protection and acquisition appeal. Management turnover and anemic 2026 revenue growth guidance (3% at midpoint) remain risks, but operational improvements are emerging.
View source ↗ - Newszacks.com·93d ago·Neutral
Here's Why You Should Retain Inogen Stock in Your Portfolio for Now INGN's POC demand, new products and international growth support its outlook, while U.S. channel shifts and distributor timing pose risks.
View source ↗ - Newszacks.com·103d ago·Neutral
Should Investors Buy Inogen as Low Valuation Meets Execution Risk? Inogen's steep sales-multiple discount, improving margins and firm international demand clash with U.S. sales and rental weakness.
View source ↗ - Newszacks.com·103d ago·Neutral
Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists INGN cuts its 2026 revenue outlook as U.S. channel pressure weighs, while international growth, new products and cost control offer support.
View source ↗ - Newszacks.com·104d ago·Neutral
Inogen Q2 Earnings Beat Estimates, Sales Rise Y/Y, 2026 View Cut INGN's Q2 revenues rise 3% as international sales climb 14.8%, but U.S. weakness led it to cut its 2026 revenue outlook.
View source ↗
Earnings
Thu, Feb 25(in 3 months)
Consensus estimate $-0.20 per share
Typical surprise +9.1% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$-0.56 vs $-0.14miss
- Thu, Aug 6$-0.14 vs $-0.15beat
- Thu, May 7$-0.30 vs $-0.24miss
- Tue, Feb 24$-0.26 vs $-0.36beat
- Wed, Nov 5$-0.20 vs $-0.22beat
- Thu, Aug 7$-0.15 vs $-0.22beat
Estimates and results for INGN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by INGN officers and directors.
- Bought
- —
- Sold
- $142k
0 trades
2 trades
- Yi Boyer Jennifer Msold
- Yi Boyer Jennifer Msold
98 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Lamar Seeligson Smithhouse · TX21 · disclosed Dec 13, 2018 (23d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
